| FENG Chong-jin,GUO Jun-bing,CHEN Yong.Clinical effect of rhEGF on acute radiation stomatitis[J].Chinese Journal of Radiological Medicine and Protection,2006,26(1):48-49 |
| Clinical effect of rhEGF on acute radiation stomatitis |
| Received:February 28, 2005 |
| DOI： |
| KeyWords:Radiation stomatitis rhEGF Treatment |
| FundProject:广东省科技计划基金资助项目(2004B34001003) |
|
| Hits: 3850 |
| Download times: 2325 |
| Abstract:: |
| Objective To evaluate the clinical effect of recombinant human epidermal growth factor(rhEGF) on acute radiation stomatitis(ARS). Methods A total of 90 patients with head and neck malignant tumor going to receive radiotherapy were randomized into 3 groups: prophylactic application group(group A);therapeutic application group(group B) and the control group(group C).The irradiated mucous membrane was sprayed with rhEGF at the beginning of radiotherapy in group A and sprayed after grade Ⅰ radiation stomatitis had appeared in group B.Comparison was made with control patients(group C) who received routine oral care with Dobell’s solution.The rate of ARS and the clinical effect of rhEGF were evaluated.Results The ARS appeared in 73%(22/30) of the patients after irradiated at a dose more than 10 Gy in group A,and appeared in 83%(25/30) of the patients irradiated at a dose less than 10 Gy in group C.In groups A and B,the rates of grades Ⅲ and Ⅳ ARS were obviously lower than those in group C.The average curative time of the rhEGF treatment groups(group A or B) was less than 7 days whereas,that of the control group (group C) was more than 10 days.The total effective rate of the rhEGF treatment groups was significantly higher than that of the control group(P<0.01). Conclusion Prophylactic application of rhEGF can postpone the development of ARS.rhEGF can reduce the incidence of grades Ⅲ and Ⅳ of ARS and shorten the curative time of ARS by either prophylactic or therapeutic application.Therefore,it should be highly recommended and popularized. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
